Author Title Type [ Year(Asc)]
Filters: Author is Antin, Joseph H  [Clear All Filters]
Herrera, A.F., Chen, L., Khajavian, S., Chase, M., Darrah, J., Maloney, D., Ho, V.T., Soiffer, R.J., Antin, J.H., Forman, S.J., et al. (2019). Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma.Biol Blood Marrow Transplant.
Bejanyan, N., Kim, S., Hebert, K.M., Kekre, N., Abdel-Azim, H., Ahmed, I., Aljurf, M., Badawy, S.M., Beitinjaneh, A., Boelens, J.Jan, et al. (2019). Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.Blood Adv3, 3123-3131.
Gooptu, M., Kim, H.T., Howard, A., Choi, S.W., Soiffer, R.J., Antin, J.H., Ritz, J., and Cutler, C.S. (2019). Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin.Biol Blood Marrow Transplant.
Newell, L.F., DeFor, T.E., Cutler, C., Verneris, M.R., Blazar, B.R., Miller, J.S., Antin, J.H., Howard, A., Wu, J., MacMillan, M.L., et al. (2019). Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant.Biol Blood Marrow Transplant.
Hamilton, B.K., Liu, Y., Hemmer, M.T., Majhail, N., Ringdén, O., Kim, D., Costa, L., Stuart, R., Alousi, A., Pidala, J.A., et al. (2019). Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
Karantanos, T., Kim, H.T., Tijaro-Ovalle, N.M., Li, L., Cutler, C., Antin, J.H., Ballen, K., Marty, F.M., Tan, C.Sabrina, Ritz, J., et al. (2019). Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4 and CD8 T effector memory cells and increase of T regulatory cells.Clin Immunol.
Whangbo, J.S., Antin, J.H., and Koreth, J. (2019). The role of regulatory T cells in graft-versus-host disease management.Expert Rev Hematol.
Giralt, S., Costa, L.J., Maloney, D., Krishnan, A., Fei, M., Antin, J.H., Brunstein, C., Geller, N., Goodman, S., Hari, P., et al. (2019). Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.Biol Blood Marrow Transplant.
Wolach, O., Stevenson, K.E., Wadleigh, M., DeAngelo, D.J., Steensma, D.P., Ballen, K.K., Soiffer, R.J., Antin, J.H., Neuberg, D.S., Ho, V.T., et al. (2016). Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.Am J Hematol.
Forcade, E., Kim, H.T., Cutler, C., Wang, K., Alho, A.C., Nikiforow, S., Ho, V.T., Koreth, J., Armand, P., Alyea, E.P., et al. (2016). Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease.Blood.
Davids, M.S., Kim, H.T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A.P., Avigan, D., Bin Chen, Y.-, McSweeney, P., et al. (2016). Ipilimumab for Patients with Relapse after Allogeneic Transplantation.N Engl J Med375, 143-153.
Herrera, A.F., Kim, H.T., Kong, K.A., Faham, M., Sun, H., Sohani, A.R., Alyea, E.P., Carlton, V.E., Bin Chen, Y.-, Cutler, C.S., et al. (2016). Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.Br J Haematol.
McDonald-Hyman, C., Flynn, R., Panoskaltsis-Mortari, A., Peterson, N., MacDonald, K.P.A., Hill, G.R., Luznik, L., Serody, J.S., Murphy, W.J., Maillard, I., et al. (2016). Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5 dependent manner.Blood.
Ion, D., Stevenson, K., Bin Woo, S.-, Ho, V.T., Soiffer, R., Antin, J.H., and Treister, N. (2014). Characterization of oral involvement in acute graft-versus-host disease.Biol Blood Marrow Transplant.
Arora, M., Hemmer, M.T., Ahn, K.Woo, Klein, J.P., Cutler, C.S., Urbano-Ispizua, A., Couriel, D.R., Alousi, A.M., Gale, R.Peter, Inamoto, Y., et al. (2014). CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort.Biol Blood Marrow Transplant.
Koreth, J., Kim, H.T., Nikiforow, S., Milford, E.L., Armand, P., Cutler, C., Glotzbecker, B., Ho, V.T., Antin, J.H., Soiffer, R.J., et al. (2014). Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival.Biol Blood Marrow Transplant.
Dubovsky, J.A., Flynn, R., Du, J., Harrington, B.K., Zhong, Y., Kaffenberger, B., Yang, C., Towns, W.H., Lehman, A., Johnson, A.J., et al. (2014). Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.J Clin Invest.
Murase, K., Kim, H.T., Bascug, O.R.Gregory, Kawano, Y., Ryan, J., Matsuoka, K.-I., Davids, M.S., Koreth, J., Ho, V.T., Cutler, C., et al. (2014). Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.Haematologica.
Eapen, M., Logan, B.R., Appelbaum, F.R., Antin, J.H., Anasetti, C., Couriel, D.R., Chen, J., Maziarz, R.T., McCarthy, P.L., Nakamura, R., et al. (2014). Long-term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy.Biol Blood Marrow Transplant.
Armand, P., Kim, H.T., Logan, B.R., Wang, Z., Alyea, E.P., Kalaycio, M.E., Maziarz, R.T., Antin, J.H., Soiffer, R.J., Weisdorf, D.J., et al. (2014). Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR.Blood.